209 related articles for article (PubMed ID: 23269519)
1. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
Ott K; Blank S; Becker K; Langer R; Weichert W; Roth W; Sisic L; Stange A; Jäger D; Büchler M; Siewert JR; Lordick F
Langenbecks Arch Surg; 2013 Feb; 398(2):239-49. PubMed ID: 23269519
[TBL] [Abstract][Full Text] [Related]
2. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
3. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
5. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
7. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases.
Becker K; Langer R; Reim D; Novotny A; Meyer zum Buschenfelde C; Engel J; Friess H; Hofler H
Ann Surg; 2011 May; 253(5):934-9. PubMed ID: 21490451
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas.
Schmidt T; Sicic L; Blank S; Becker K; Weichert W; Bruckner T; Parakonthun T; Langer R; Büchler MW; Siewert JR; Lordick F; Ott K
Br J Cancer; 2014 Apr; 110(7):1712-20. PubMed ID: 24569472
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
[TBL] [Abstract][Full Text] [Related]
11. Importance of residual primary cancer after induction therapy for esophageal adenocarcinoma.
Raja S; Rice TW; Ehrlinger J; Goldblum JR; Rybicki LA; Murthy SC; Adelstein D; Videtic G; McNamara MP; Blackstone EH
J Thorac Cardiovasc Surg; 2016 Sep; 152(3):756-761.e5. PubMed ID: 27530636
[TBL] [Abstract][Full Text] [Related]
12. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer.
Shaikh T; Zaki MA; Dominello MM; Handorf E; Konski AA; Cohen SJ; Shields A; Philip P; Meyer JE
Acta Oncol; 2016; 55(3):303-8. PubMed ID: 26581671
[TBL] [Abstract][Full Text] [Related]
13. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
14. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.
Blank S; Stange A; Sisic L; Roth W; Grenacher L; Sterzing F; Burian M; Jäger D; Büchler M; Ott K
Langenbecks Arch Surg; 2013 Feb; 398(2):211-20. PubMed ID: 23224565
[TBL] [Abstract][Full Text] [Related]
15. Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.
Cabau M; Luc G; Terrebonne E; Belleanne G; Vendrely V; Sa Cunha A; Collet D
Am J Surg; 2013 Jun; 205(6):711-7. PubMed ID: 23422318
[TBL] [Abstract][Full Text] [Related]
16. Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study.
Francoual J; Lebreton G; Bazille C; Galais MP; Dupont B; Alves A; Lubrano J; Morello R; Menahem B
J Visc Surg; 2018 Oct; 155(5):365-374. PubMed ID: 29501383
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
18. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A.
Fujitani K; Nakamura K; Mizusawa J; Kuwata T; Shimoda T; Katayama H; Kushima R; Taniguchi H; Yoshikawa T; Boku N; Terashima M; Fukuda H; Sano T; Sasako M;
Gastric Cancer; 2021 Jan; 24(1):197-204. PubMed ID: 32572792
[TBL] [Abstract][Full Text] [Related]
19. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
20. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
